At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 202 enrolled
Drug / intervention
hATG +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.
European Society for Blood and Marrow Transplantation·interventional·Posted Mar 31, 2014·Updated Apr 24, 2026
In Brief
A Phase 3 clinical trial evaluating hATG, CsA, and 1 other intervention for Severe Aplastic Anemia. Completed, enrolled 202 participants across 29 sites in 6 countries.
Detailed Summary
The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Aplastic Anemia
CountriesFrance, Italy, Netherlands, Spain, Switzerland, United Kingdom
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartJul 2015
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 31, 2014
Enrollment StartJul 1, 2015
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 12.3 years ago
Interventions
hATGdrug
CsAdrug
Eltrombopagdrug